These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Perspectives for treating Alzheimer's disease: a review on promising pharmacological substances. Cazarim Mde S; Moriguti JC; Ogunjimi AT; Pereira LR Sao Paulo Med J; 2016; 134(4):342-54. PubMed ID: 27557144 [TBL] [Abstract][Full Text] [Related]
4. Editorial: Collaborative Efforts to Prevent Alzheimer's Disease. Touchon J; Rosenbaum J; Aisen P; Andrieu S; Carrillo MC; Ceccaldi M; Dartiques JF; Feldman H; Gabelle A; Isaac M; Fitten LJ; Sperling RA; Vellas B; Tariot P; Weiner M J Nutr Health Aging; 2017; 21(10):1072-1074. PubMed ID: 29188862 [No Abstract] [Full Text] [Related]
5. Developing a pathway to support the appropriate, affordable, and widespread use of effective Alzheimer's prevention drugs. Reiman EM; Mattke S; Kordower JH; Khachaturian ZS; Khachaturian AS Alzheimers Dement; 2022 Jan; 18(1):7-9. PubMed ID: 35103395 [No Abstract] [Full Text] [Related]
6. Demographic characteristics of participants in clinical trials to treat Alzheimer disease, 2008-2023. Zhang AD; Anderson TS; Hastings SN J Am Geriatr Soc; 2024 Mar; 72(3):942-945. PubMed ID: 37916640 [No Abstract] [Full Text] [Related]
7. Hormonal treatment, mild cognitive impairment and Alzheimer's disease. Ryan J; Scali J; Carriere I; Ritchie K; Ancelin ML Int Psychogeriatr; 2008 Feb; 20(1):47-56. PubMed ID: 18072983 [TBL] [Abstract][Full Text] [Related]
8. Current and future treatments for cognitive deficits in dementia. McLendon BM; Chen GG; Doraiswamy PM Curr Psychiatry Rep; 2000 Feb; 2(1):20-3. PubMed ID: 11122927 [TBL] [Abstract][Full Text] [Related]
9. Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. Wright JW; Stubley L; Pederson ES; Kramár EA; Hanesworth JM; Harding JW J Neurosci; 1999 May; 19(10):3952-61. PubMed ID: 10234025 [TBL] [Abstract][Full Text] [Related]
10. Prescribing patterns for nursing home residents in the US. The reality and the vision. Broderick E Drugs Aging; 1997 Oct; 11(4):255-60. PubMed ID: 9342555 [TBL] [Abstract][Full Text] [Related]
11. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Du Yan S; Zhu H; Fu J; Yan SF; Roher A; Tourtellotte WW; Rajavashisth T; Chen X; Godman GC; Stern D; Schmidt AM Proc Natl Acad Sci U S A; 1997 May; 94(10):5296-301. PubMed ID: 9144231 [TBL] [Abstract][Full Text] [Related]
12. Widespread peroxynitrite-mediated damage in Alzheimer's disease. Smith MA; Richey Harris PL; Sayre LM; Beckman JS; Perry G J Neurosci; 1997 Apr; 17(8):2653-7. PubMed ID: 9092586 [TBL] [Abstract][Full Text] [Related]
13. Changes in the elastic properties of cholinergic synaptic vesicles as measured by atomic force microscopy. Laney DE; Garcia RA; Parsons SM; Hansma HG Biophys J; 1997 Feb; 72(2 Pt 1):806-13. PubMed ID: 9017205 [TBL] [Abstract][Full Text] [Related]
14. How can we live forever? Kirkwood T BMJ; 1996 Dec 21-28; 313(7072):1571. PubMed ID: 8990987 [No Abstract] [Full Text] [Related]
17. Pharmacologic approaches to cognitive deficits in Alzheimer's disease. Peskind ER J Clin Psychiatry; 1998; 59 Suppl 9():22-7. PubMed ID: 9720483 [TBL] [Abstract][Full Text] [Related]
18. Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II--Pharmacologic therapy. Alzheimer's Disease (AD) Managed Care Advisory Council. Fillit H; Cummings J Manag Care Interface; 2000 Jan; 13(1):51-6. PubMed ID: 10747691 [TBL] [Abstract][Full Text] [Related]